Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, “Bexxar”)

Part of the Medical Radiology book series (MEDRAD)


The rationale for the use of radioimmunotherapy (RIT) in cancer is that radiolabeled monoclonal antibodies specifically target and irradiate tumor cells while sparing normal tissues. The specific tumor targeting theoretically allows higher doses of radiation to be delivered to tumor as compared to external beam radiation because the effects of the radiation on normal tissues is lesser with RIT. An additional advantage of RIT is that the beta-emissions of the radiolabel target surrounding malignant cells via the cross-fire effect, probably killing those not reached by unlabeled antibody. Tositumomab and Iodine (I 131) tositumomab (Bexxar® therapeutic regimen) is RIT directed against the CD20 antigen which is effective for the treatment of B-cell non-Hodgkin lymphoma (NHL). This chapter discusses the rationale, development, clinical applications and practical aspects of delivering tositumomab and Iodine (I 131) tositumomab (Bexxar® therapeutic regimen).


Follicular Lymphoma Total Lesion Glycolysis Unlabeled Antibody Total Body Radiation Dose Total Body Dose 


  1. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM (1984) Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63(6):1424–1433PubMedGoogle Scholar
  2. Aviles A, Neri N, Delgado S, Perez F, Nambo MJ, Cleto S, Talavera A, Huerta-Guzman J (2005) Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol 22(4):383–387PubMedCrossRefGoogle Scholar
  3. Beers SA, French RR, Chan HT, Lim SH, Jarrett TC, Vidal RM, Wijayaweera SS, Dixon SV, Kim H, Cox KL, Kerr JP, Johnston DA, Johnson PW, Verbeek JS, Glennie MJ, Cragg MS (2010) Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115(25):5191–5201PubMedCrossRefGoogle Scholar
  4. Bexxar package insert (2003) GlaxoSmithKline, SeattleGoogle Scholar
  5. Bodet-Milin C, Kraeber-Bodere F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D (2008) Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography. Haematologica 93(3):390–397PubMedCrossRefGoogle Scholar
  6. Boross P, Leusen JH (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2(6):676–690PubMedCentralPubMedGoogle Scholar
  7. Brown RS, Kaminski MS, Fisher SJ, Chang AE, Wahl RL (1997) Intratumoral microdistribution of [131I]MB-1 in patients with B-cell lymphoma following radioimmunotherapy. Nucl Med Biol 24(7):657–663PubMedCrossRefGoogle Scholar
  8. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS (1992) Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 52(3):637–642PubMedGoogle Scholar
  9. Calais PJ, Turner JH (2012) Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin’s Lymphoma. World J Nucl Med 11(3):110–116PubMedCentralPubMedCrossRefGoogle Scholar
  10. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G (2002) Binding to CD20 by anti-B1 antibody or F(ab’)(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 51(1):15–24PubMedCrossRefGoogle Scholar
  11. Cazaentre T, Morschhauser F, Vermandel M, Betrouni N, Prangere T, Steinling M, Huglo D (2010) Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37(3):494–504PubMedCrossRefGoogle Scholar
  12. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25(27):4285–4292Google Scholar
  13. Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SJ (2004) The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 10(23):7792–7798PubMedCrossRefGoogle Scholar
  14. DeNardo GL, DeNardo SJ, O’Grady LF, Levy NB, Adams GP, Mills SL (1990) Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 50(3 Suppl):1014s–1016sPubMedGoogle Scholar
  15. Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP (2006) Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma. Cancer 106(3):616–622PubMedCrossRefGoogle Scholar
  16. Gates VL, Carey JE, Siegel JA, Kaminski MS, Wahl RL (1998) Nonmyeloablative iodine-131 anti-B1 radioimmunotherapy as outpatient therapy. J Nucl Med 39(7):1230–1236PubMedGoogle Scholar
  17. Gisselbrecht C, Vose J, Nademanee A, Gianni AM, Nagler A (2009) Radioimmunotherapy for stem cell transplantation in non-Hodgkin’s lymphoma: in pursuit of a complete response. Oncologist 14(Suppl 2):41–51PubMedCrossRefGoogle Scholar
  18. Goldsmith SJ (2010) Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 40(2):122–35Google Scholar
  19. Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM (2008) Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112(3):830–835PubMedCentralPubMedCrossRefGoogle Scholar
  20. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, Goris M (2005) Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23(4):712–719CrossRefGoogle Scholar
  21. Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ, Du Y, Lewington V, Smart J, Thom J, Zivanovic M, Johnson PW (2009) Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113(7):1412–1421PubMedCrossRefGoogle Scholar
  22. Jacene HA, Filice R, Kasecamp W, Wahl RL (2007) Comparison of 90Y-Ibritumomab tiuxetan and 131I-Tositumomab in clinical practice. J Nucl Med 48(11):1767–1776PubMedCrossRefGoogle Scholar
  23. Jacene HA, Filice R, Kasecamp W, Wahl RL (2009) 18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50(1):8–17PubMedCrossRefGoogle Scholar
  24. Johnson P, Glennie M (2003) The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol 30(1 Suppl 2):3–8PubMedCrossRefGoogle Scholar
  25. Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM (1999) Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 5(10 Suppl):3292s–3303sPubMedGoogle Scholar
  26. Kaminski MS, Fig LM, Zasadny KR, Koral KF, DelRosario RB, Francis IR, Hanson CA, Normolle DP, Mudgett E, Liu CP et al (1992) Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10(11):1696–1711PubMedGoogle Scholar
  27. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, Crawford SM, Burgess JM, Petry NA, Butchko GM et al (1993) Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody. N Engl J Med 329(7):459–465PubMedCrossRefGoogle Scholar
  28. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, Regan D, Fisher S, Gutierrez J, Kroll S, Stagg R, Tidmarsh G, Wahl RL (2000) Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96(4):1259–1266PubMedGoogle Scholar
  29. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, Lister TA, Stagg RJ, Tidmarsh GF, Kroll S, Wahl RL, Knox SJ, Vose JM (2001) Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 19(19):3918–3928PubMedGoogle Scholar
  30. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005) 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352(5):441–449PubMedCrossRefGoogle Scholar
  31. Mason DY et al (1990) Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. pp 1215–1222.Google Scholar
  32. Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A (2013) 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J Clin Oncol 31(16):1977–1983PubMedCrossRefGoogle Scholar
  33. Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf H, Amox DG, Simoni JL, Starr RJ, Green MR, Royston I (1990) Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50(3 Suppl):1022s–1028sPubMedGoogle Scholar
  34. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI, Southwest Oncology G (2006) Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24(25):4143–4149PubMedCrossRefGoogle Scholar
  35. Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI (2013) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol 31(3):314–320PubMedCentralPubMedCrossRefGoogle Scholar
  36. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL (2010) Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 51(6):987–994PubMedCrossRefGoogle Scholar
  37. Scheinberg DA, Straus DJ, Yeh SD, Divgi C, Garin-Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ (1990) A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin’s lymphoma: effects of tumor burden and antigen expression. J Clin Oncol 8(5):792–803PubMedGoogle Scholar
  38. Seldin DW (2002) Techniques for Using Bexxar for the Treatment of Non-Hodgkin’s Lymphoma. J Nucl Med Technol 30(3):109–114Google Scholar
  39. Song H, Du Y, Sgouros G, Prideaux A, Frey E, Wahl RL (2007) Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin’s lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis. J Nucl Med 48(1):150–157PubMedCentralPubMedGoogle Scholar
  40. Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125(4):1678–1685PubMedGoogle Scholar
  41. Tedder TF, Boyd AW, Freedman AS, Nadler LM, Schlossman SF (1985) The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 135(2):973–979PubMedGoogle Scholar
  42. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL (2000) Metabolic response of non-Hodgkin’s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 41(6):999–1005PubMedGoogle Scholar
  43. Vose JM, Wahl RL, Saleh M, Rohatiner AZ, Knox SJ, Radford JA, Zelenetz AD, Tidmarsh GF, Stagg RJ, Kaminski MS (2000) Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol 18(6):1316–1323PubMedGoogle Scholar
  44. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31(13):1662–1668PubMedCentralPubMedCrossRefGoogle Scholar
  45. Wahl RL (2005) Tositumomab and (131)I therapy in non-Hodgkin’s lymphoma. J Nucl Med 46(1 suppl):128S–140S.Google Scholar
  46. Wahl RL, Kroll S, Zasadny KR (1998a) Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 39(8 Suppl):14S–20SGoogle Scholar
  47. Wahl RL, Zasadny KR, MacFarlane D, Francis IR, Ross CW, Estes J, Fisher S, Regan D, Kroll S, Kaminski MS (1998b) Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 39(8 Suppl):21S–27SGoogle Scholar
  48. Wilson A (2008) Non-Hodgkin’s lymphoma. In: Abeloff M, Niederhuber JE, Kastan MB, McKenna WG (eds) Abeloff’s clinical oncology. Churchill Livingstone Elsevier, PhiladelphiaGoogle Scholar
  49. Zevalin package insert (2009) Spectrum Pharmaceuticals, Inc, IrvineGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Nuclear Medicine, Department of Imaging, Dana-Farber Cancer InstituteRadiology, Harvard Medical SchoolBostonUSA
  2. 2.Division of Nuclear Medicine and PET CenterThe Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Room 3223 Johns Hopkins Outpatient CenterBaltimoreUSA

Personalised recommendations